Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Saved in:
| Title: | Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. |
|---|---|
| Authors: | Cramer P; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., von Tresckow J; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Fink AM; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Robrecht S; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Giza A; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Tausch E; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Müller L; Practice for Hematology and Oncology UnterEms, Leer, Germany., Knauf W; Practice for Hematology and Oncology Bethanien, Frankfurt/Main, Germany., Zingerle M; Practice for Hematology and Oncology Pasing and Fürstenfeldbruck, Munich, Germany., Al-Sawaf O; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Langerbeins P; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Fischer K; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Kreuzer KA; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Kneba M; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany., Wendtner CM; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany., Stilgenbauer S; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Eichhorst B; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Hallek M; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. |
| Source: | American journal of hematology [Am J Hematol] 2024 Jun; Vol. 99 (6), pp. 1192-1195. Date of Electronic Publication: 2024 Apr 05. |
| Publication Type: | Letter; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7610369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-8652 (Electronic) Linking ISSN: 03618609 NLM ISO Abbreviation: Am J Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38578022 AccessLevel: 2 PubType: Report PubTypeId: report PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Cramer+P%22">Cramer P</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22von+Tresckow+J%22">von Tresckow J</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.; Clinic for Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.<br /><searchLink fieldCode="AU" term="%22Fink+AM%22">Fink AM</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Robrecht+S%22">Robrecht S</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Giza+A%22">Giza A</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Tausch+E%22">Tausch E</searchLink>; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Müller+L%22">Müller L</searchLink>; Practice for Hematology and Oncology UnterEms, Leer, Germany.<br /><searchLink fieldCode="AU" term="%22Knauf+W%22">Knauf W</searchLink>; Practice for Hematology and Oncology Bethanien, Frankfurt/Main, Germany.<br /><searchLink fieldCode="AU" term="%22Zingerle+M%22">Zingerle M</searchLink>; Practice for Hematology and Oncology Pasing and Fürstenfeldbruck, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Al-Sawaf+O%22">Al-Sawaf O</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Langerbeins+P%22">Langerbeins P</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Fischer+K%22">Fischer K</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kreuzer+KA%22">Kreuzer KA</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kneba+M%22">Kneba M</searchLink>; Department of Internal Medicine II, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany.<br /><searchLink fieldCode="AU" term="%22Wendtner+CM%22">Wendtner CM</searchLink>; Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Munich Clinic Schwabing, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Stilgenbauer+S%22">Stilgenbauer S</searchLink>; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.<br /><searchLink fieldCode="AU" term="%22Eichhorst+B%22">Eichhorst B</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Hallek+M%22">Hallek M</searchLink>; Department I of Internal Medicine and German CLL Study Group; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%227610369%22">American journal of hematology</searchLink> [Am J Hematol] 2024 Jun; Vol. 99 (6), pp. 1192-1195. <i>Date of Electronic Publication: </i>2024 Apr 05. – Name: TypePub Label: Publication Type Group: TypPub Data: Letter; Multicenter Study; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Blackwell%22">Wiley-Blackwell </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7610369 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1096-8652 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203618609%22">03618609 </searchLink><i>NLM ISO Abbreviation: </i>Am J Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38578022 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/ajh.27304 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1192 Titles: – TitleFull: Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Cramer P – PersonEntity: Name: NameFull: von Tresckow J – PersonEntity: Name: NameFull: Fink AM – PersonEntity: Name: NameFull: Robrecht S – PersonEntity: Name: NameFull: Giza A – PersonEntity: Name: NameFull: Tausch E – PersonEntity: Name: NameFull: Müller L – PersonEntity: Name: NameFull: Knauf W – PersonEntity: Name: NameFull: Zingerle M – PersonEntity: Name: NameFull: Al-Sawaf O – PersonEntity: Name: NameFull: Langerbeins P – PersonEntity: Name: NameFull: Fischer K – PersonEntity: Name: NameFull: Kreuzer KA – PersonEntity: Name: NameFull: Kneba M – PersonEntity: Name: NameFull: Wendtner CM – PersonEntity: Name: NameFull: Stilgenbauer S – PersonEntity: Name: NameFull: Eichhorst B – PersonEntity: Name: NameFull: Hallek M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1096-8652 Numbering: – Type: volume Value: 99 – Type: issue Value: 6 Titles: – TitleFull: American journal of hematology Type: main |
| ResultId | 1 |
